<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>International Journal of Preventive Medicine (Int J Prev Med)</JournalTitle><Issn>2008-7802</Issn><Volume>1</Volume><Issue>3</Issue><PubDate PubStatus="epublish"><Year>2017</Year><Month>09</Month><Day>10</Day></PubDate></Journal><title locale="en_US">Is Cost of Medication for Quit Smoking Important for Smokers, Experience of Using Champix in Iranian Smoking Cessation Program 2016</title><FirstPage>1819</FirstPage><LastPage>1819</LastPage><Language>EN</Language><AuthorList><Author><affiliation locale="en_US">Tobacco Prevention and Control Research Center,&#13;
National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran</affiliation></Author></AuthorList><History><PubDate PubStatus="received"><Year>2017</Year><Month>09</Month><Day>10</Day></PubDate></History><abstract locale="en_US">&lt;p&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Background&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;Providing smoking cessation services are special importance to tobacco control programs. To date, Champix is a new expensive medication for smoking cessation available nationally. Champix has both agonist and antagonist activities and can reduce nicotine dependence&lt;br /&gt;and withdrawal symptoms. The purpose of this study was to evaluate the duration of using Champix based on its cost. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Methods&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;This quasi‑experimental study was conducted with smokers presenting to the Tanaffos Smoking Cessation Clinic in Tehran, Iran 2016. Smokers were visited by a physician 3 times at 1‑week intervals for counseling. Smokers started to use Champix and stopped smoking in&lt;br /&gt;the 2nd week of counseling and were followed up by phone and through regular visits to the clinic at 1, 3, and 6 months postintervention. Some of them did not continue medication for 12 weeks because of its cost. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Results&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;A total of 227 smokers including 133 males (58%) with a mean age of 43 years were enrolled of whom 116 (51.1%), 89 (43.6%), and 34 (20.6%) had quit smoking after 1, 3, and 6 months, respectively. Quit rates were signifcantly higher among those who used Champix for more than 6 weeks, and this rate was not correlated with age, sex, educational level, or nicotine dependence. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Conclusions&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;Use of Champix for more than 6 weeks increases the quitting success rate compared with using for a shorter time. The cost of Champix was important for smokers and adding Champix to the list of insurance medication or getting it free of charge is needed.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span class="fontstyle0" style="color: #00652e;"&gt;&lt;strong&gt;Keywords&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle3"&gt;Champix, quit, smoking&lt;/span&gt; &lt;br style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;" /&gt;&lt;/p&gt;</abstract><web_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/1819</web_url><pdf_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/download/1819/2108</pdf_url></Article></Articles>
